|Bid||0.00 x 1100|
|Ask||8.00 x 1000|
|Day's Range||5.62 - 6.11|
|52 Week Range||2.91 - 9.50|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the expansion of its infectious disease pipeline by entering into an agreement in principle to acquire an exclusive, license for a treatment under development aimed to treat the Hepatitis B Virus (HBV) infections from G-Tech Bio, LLC. An abstract accepted for presentation at the HepDART meeting featuring in vivo and in vitro data from preclinical studies conducted with this novel HBV treatment candidate will be presented by Dr. Serhat Gümrükcü, MD, PhD on December 10, 2019. Approximately 5 percent of the world’s population is infected with HBV, and around 1 million people per year die from the disease.
New York, New York--(Newsfile Corp. - November 21, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Enochain Biosciences, Inc. (NASDAQ: ENOB) ("Enochain" or the "Company").Faruqi & Faruqi logoIf you invested in Enochain stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/ENOB. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to using its genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV and to potentially provide life-long cancer remission of some of the deadliest cancers.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! These days it's easy to simply buy an index fund, and your returns should (roughly) match the m...
As with “the Berlin patient,” the first person to be considered “cured” of HIV a decade ago, the intervention utilized in the London patient was performed primarily to treat an HIV-associated cancer. Both patients received transplants with cells from allogeneic donors who have a naturally occurring mutation (CCR5D32) which makes the individuals’ T cells resistant to infection by many types of HIV. These allogeneic bone marrow transplantation procedures require myeloablative chemotherapy, a radical intervention that carries significant medical risks and considerable expense. Given the success of anti-retroviral medicines in managing HIV, this approach is not considered a medically necessary or viable treatment option for HIV-positive persons who do not already require an allogeneic transplant to treat another disease, such as cancer.
With the advent of new approaches to medical care, as well as innovative medical technologies coming out of the healthcare industry, news surrounding innovative companies putting their skills to the test in the has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Titan Pharmaceuticals Inc (TTNP), Aileron Therapeutics Inc (ALRN), Enochian Biosciences Inc (ENOB) represent four healthcare stocks setting the pace on Friday afternoon. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
NEW YORK , Jan. 16, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2018 performance ...
Enochian Biosciences, Inc. (“Enochian”) a biopharmaceutical company focused on the development and commercialization of novel therapies for HIV/AIDS and oncology, announced today that the Company’s new Executive Vice-Chair, Dr. Mark Dybul will be taking over the leadership of the Company following the departure of Eric Leire as Chief Executive Officer. Dr. Dybul had previously served as Chair of the Company’s Scientific Advisory Board beginning in August of 2017, and as a director since February of 2018.
A look at the shareholders of Enochian Biosciences Inc. (NASDAQ:ENOB) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...